Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood bought shares of SpaceX, Roblox, and Alamar Biosciences, with the article framing these as opportunistic adds after recent weakness. SpaceX is only 3% above its first trade after six trading days and trades at more than 100x trailing revenue, Roblox is down more than 50% over the past year amid declining sequential users and engagement, and Alamar remains near its IPO price after April revenue nearly doubled to $26 million. The piece is more commentary on Ark Invest positioning and post-IPO volatility than a major catalyst.

Analysis

The common thread is not “Cathie bought growth” but that she is leaning into post-listing dislocations where public-market price discovery is still unstable. That matters because these names sit at different points on the same risk spectrum: SpaceX is a duration asset with latent optionality, Roblox is a consumer engagement story facing momentum risk, and Alamar is an early commercial biotech platform where small absolute revenue inflections can re-rate the stock sharply. The second-order effect is that active growth allocators may use these prints as validation signals, which can create short-lived technical support even when fundamentals are uneven.

Roblox is the cleanest short-duration setup because the market is already focused on the deceleration in engagement on a sequential basis, not the year-over-year optics. If engagement keeps rolling over into the next quarter, multiple compression can outpace any revenue resilience from pricing or monetization improvements; if usage stabilizes, the stock can squeeze because sentiment is already heavily negative. The key catalyst window is the next earnings cycle, where management guidance on retention, bookings, and creator economics will likely matter more than headline user counts.

SpaceX is a different trade: the near-term risk is less fundamental and more mechanical, with a post-IPO holder base still being discovered. That creates an air pocket if early investors or arbitrage capital de-risks, but it also means any operational milestone on Starship or Starlink can reset the narrative quickly. Alamar is the underappreciated sleeper because its valuation sensitivity is tied to instrument placements and consumable pull-through; if the company demonstrates even modest repeatability in revenue growth, biotech growth capital can crowd in fast due to the scarcity of commercial-stage proteomics names.

The consensus may be underestimating how much of Roblox’s weakness is sentiment-driven versus structural, but it may also be overestimating how quickly SpaceX can be modeled like a normal public company. The best risk/reward is likely in relative value rather than outright direction: short the weakest engagement-momentum name against the most durable platform. For biotech, the market often rewards proof of commercial traction far earlier than profitability, so a small position can have convex upside if execution persists into the next two quarters.

Key Decisions for Investors

• Short RBLX into the next earnings window; use a 4-8 week horizon and size for a catalyst-driven move. Risk/reward improves if engagement metrics continue declining sequentially, with the stop tied to any stabilization in hours engaged or DAU momentum.
• Pair trade: long ALMR / short a basket of higher-burn, pre-commercial biotech names over the next 2-3 quarters. The thesis is that early revenue proof plus razor-and-blades economics can re-rate faster than names still dependent on future pipeline events.
• Treat SpaceX as a volatility event, not a clean directional long right now; consider buying pullbacks only after liquidity settles over the next few weeks. If Starship or Starlink newsflow turns positive, the stock can re-rate sharply, but near-term holder overhang argues for patience.
• For tactically bullish investors, use call spreads on RBLX only after an earnings washout, not before. The setup is better for a mean-reversion trade than a fundamental long until sequential engagement trends inflect.
• Watch ALMR for instrument/consumable mix commentary over the next 1-2 quarters; add on evidence that consumables are scaling faster than placements. That would confirm operating leverage and justify a higher multiple before profitability arrives.